Skip to main content

Advertisement

SpringerLink
Log in

Drug-Induced Lupus Anticoagulants and Antiphospholipid Antibodies

  • ANTIPHOSPHOLIPID SYNDROME (RAS ROUBEY, SECTION EDITOR)
  • Published:
Current Rheumatology Reports Aims and scope Submit manuscript

Abstract

Lupus anticoagulants (LA) are immunoglobulins (IgG, IgM, and/or IgA) which interfere with one or more of phospholipid-dependent in vitro coagulation tests, eg, activated partial thromboplastin time (aPTT), kaolin clotting time (KCT), dilute Russell viper venom time (dRVVT), and dilute prothrombin time (dPT). LAs may be seen in a variety of clinical settings including the primary antiphospholipid syndrome (APS), systemic lupus erythematosus (SLE), other autoimmune diseases, secondary to infections, malignancies, and in association with certain drugs. LAs associated with the antiphospholipid syndrome and other autoimmune disease recognize certain phospholipid-binding proteins (β2-glycoprotein I [β2GPI] or prothrombin). Many drugs have been implicated as possibly causing LAs, although the majority of such cases are limited to a select few. Drug-induced LAs are heterogeneous, differing in laboratory findings as well as related clinical complications. This paper reviews the English medical literature on drug-induced LA and potential mechanisms of induction.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Conley CL, Hartmann RC. A hemorrhagic disorder caused by circulating anticoagulant in patients with disseminated lupus erythematosus. J Clin Invest. 1952;31:621–2.

    Google Scholar 

  2. Shapiro SS. The lupus anticoagulant/antiphospholipid syndrome. Annu Rev Med. 1996;47:533–53.

    Article  PubMed  CAS  Google Scholar 

  3. Lechner K. Acquired inhibitors in nonhemophilic patients. Haemostasis. 1974;3:65–93.

    PubMed  CAS  Google Scholar 

  4. Bowie EJW, Thompson Jr JH, Pascuzzi CA, Owen Jr CA. Thrombosis in systemic lupus erythematosus despite circulating anticoagulants. J Lab Clin Med. 1963;62:416–30.

    PubMed  CAS  Google Scholar 

  5. Feinstein DI, Rapaport SI. Acquired inhibitors of blood coagulation. Prog Hemostas Thromb. 1972;1:75–95.

    CAS  Google Scholar 

  6. Schroeder HA, Morrow JD, Perry Jr HM. Studies on the control of hypertension by hyphex. I. Effects on blood pressure. Circulation. 1953;8(5):672–80.

    PubMed  CAS  Google Scholar 

  7. Lindqvist TT. Lupus erythematosus disseminatus after administration of mesantoin; report of two cases. Acta Med Scand. 1957;158(2):131–8.

    Article  PubMed  CAS  Google Scholar 

  8. Ladd AT. Procainamide-induced lupus erythematosus. N Engl J Med. 1962;267:1357–8.

    Article  PubMed  CAS  Google Scholar 

  9. Borchers AT, Keen CL, Gershwin ME. Drug-induced lupus. Ann N Y Acad Sci. 2007;1108:166–82.

    Article  PubMed  CAS  Google Scholar 

  10. Schleider MA, Nachman RL, Jaffe EA, Coleman M. A clinical study of the lupus anticoagulant. Blood. 1976;48(4):499–509.

    PubMed  CAS  Google Scholar 

  11. Bell WR, Boss GR, Wolfson JS. Circulating anticoagulant in the procainamide-induced lupus syndrome. Arch Intern Med. 1977;137(10):1471–3.

    Article  PubMed  CAS  Google Scholar 

  12. Davis S, Furie BC, Griffin JH, Furie B, Willey R. Circulating inhibitors of blood coagulation associated with procainamide-induced lupus erythematosus. Am J Hematol. 1978;4(4):401–7.

    Article  PubMed  CAS  Google Scholar 

  13. Galanakis DK, Newman J, Summers D. Circulating thrombin time anticoagulant in a procainamide-induced syndrome. JAMA. 1978;239(18):1873–4.

    Article  PubMed  CAS  Google Scholar 

  14. Mueh JR, Herbst KD, Rapaport SI. Thrombosis in patients with the lupus anticoagulant. Ann Intern Med. 1980;92:156–9.

    PubMed  CAS  Google Scholar 

  15. Edwards RL, Rick ME, Wakem CJ. Studies on a circulating anticoagulant in procainamide-induced lupus erythematosus. Arch Intern Med. 1981;141(12):1688–90.

    Article  PubMed  CAS  Google Scholar 

  16. Sanfelippo MJ, Drayna CJ. Prekallikrein inhibition associated with the lupus anticoagulant: a mechanism of thrombosis. Am J Clin Pathol. 1982;77:275–9.

    PubMed  CAS  Google Scholar 

  17. O’Brien DC, Shimomura SK. Procainamide and the lupus anticoagulant. Drug Intell Clin Pharm. 1984;18:971.

    Google Scholar 

  18. Gastineau DA, Kazmier FJ, Nichols WL, Bowie EJ. Lupus anticoagulant: an analysis of the clinical and laboratory features of 219 cases. Am J Hematol. 1985;19:265–75.

    Article  PubMed  CAS  Google Scholar 

  19. Day HJ, Cherrey R, O'Hara D, Carebello J. Incidence of procainamide-induced anticoagulant. Thromb Haemost. 1987;58:394. Ref Type: Abstract.

    Google Scholar 

  20. Weber MT, Hocking WG. Procainamide induced lupus anticoagulant. Wis Med J. 1988;87(9):30–2.

    PubMed  CAS  Google Scholar 

  21. Heyman MR, Flores RH, Edelman BB, Carliner NH. Procainamide-induced lupus anticoagulant. South Med J. 1988;81(7):934–6.

    Article  PubMed  CAS  Google Scholar 

  22. Li GC, Greenberg CS, Currie MS. Procainamide-induced lupus anticoagulants and thrombosis. South Med J. 1988;81(2):262–4.

    Article  PubMed  CAS  Google Scholar 

  23. Schlesinger PA, Peterson LA. Procainamide-associated lupus anticoagulants and thrombotic events. Arthritis Rheum. 1988;31:S54. Ref Type: Abstract.

    Google Scholar 

  24. Asherson RA, Zulman J, Hughes GR. Pulmonary thromboembolism associated with procainamide induced lupus syndrome and anticardiolipin antibodies. Ann Rheum Dis. 1989;48:232–5.

    Article  PubMed  CAS  Google Scholar 

  25. Kushner M, Simonian N. Lupus anticoagulants, anticardiolipin antibodies, and cerebral ischemia. Stroke. 1989;20:225–9.

    Article  PubMed  CAS  Google Scholar 

  26. List AF, Doll DC. Thrombosis associated with procainamide-induced lupus anticoagulant. Acta Haematol. 1989;82(1):50–2.

    Article  PubMed  CAS  Google Scholar 

  27. Humphries JE. Persistent procainamide-associated lupus anticoagulant. Clin Hemost Rev. 1996;10:13.

    Google Scholar 

  28. Merrill JT, Shen C, Gugnani M, Lahita RG, Mongey AB. High prevalence of antiphospholipid antibodies in patients taking procainamide. J Rheumatol. 1997;24(6):1083–8.

    PubMed  CAS  Google Scholar 

  29. Freeman NJ, Fajardo L, Carvalho A. Simultaneous procainamide-induced immune thrombocytopenia and lupus anticoagulant. Am J Hematol. 1995;48(2):133–4.

    PubMed  CAS  Google Scholar 

  30. Kameda H, Mimori T, Kaburaki J, Fujii T, Takahashi T, Akaishi M, et al. Systemic sclerosis complicated by procainamide-induced lupus and antiphospholipid syndrome. Br J Rheumatol. 1998;37(11):1236–9.

    Article  PubMed  CAS  Google Scholar 

  31. Triplett DA, Brandt JT, Musgrave KA, Orr CA. The relationship between lupus anticoagulants and antibodies to phospholipid. JAMA. 1988;259:550–4.

    Article  PubMed  CAS  Google Scholar 

  32. Walker TS, Triplett DA, Javed N, Musgrave K. Evaluation of lupus anticoagulants: antiphospholipid antibodies, endothelium associated immunoglobulin, endothelial prostacyclin secretion, and antigenic protein S levels. Thromb Res. 1988;51:267–81.

    Article  PubMed  CAS  Google Scholar 

  33. Clyne LP, Farber LR, Chopyk RL. Procainamide-induced circulating anticoagulants in a congenitally-deficient factor XI patient. Folia Haematol Int Mag Klin Morphol Blutforsch. 1989;116(2):239–44.

    PubMed  CAS  Google Scholar 

  34. Triplett DA, Brandt JT, Kaczor D, Schaeffer J. Laboratory diagnosis of lupus inhibitors: a comparison of the tissue thromboplastin inhibition procedure with a new platelet neutralization procedure. Am J Clin Pathol. 1983;79(6):678–82.

    PubMed  CAS  Google Scholar 

  35. Blomgren SE, Condemi JJ, Bignall MC, Vaughan JH. Antinuclear antibody induced by procainamide. A prospective study. N Engl J Med. 1969;281(2):64–6.

    Article  PubMed  CAS  Google Scholar 

  36. Bird MR, O’Neill AI, Buchanan RR, Ibrahim KM, Des PJ. Lupus anticoagulant in the elderly may be associated with both quinine and quinidine usage. Pathology. 1995;27(2):136–9.

    Article  PubMed  CAS  Google Scholar 

  37. Lavie CJ, Biundo J, Quinet RJ, Waxman J. Systemic lupus erythematosus (SLE) induced by quinidine. Arch Intern Med. 1985;145(3):446–8.

    Article  PubMed  CAS  Google Scholar 

  38. Jeffrey RF. Transient lupus anticoagulant and fansidar therapy. Postgrad Med J. 1986;62:893–4.

    Article  PubMed  CAS  Google Scholar 

  39. Canoso RT, Hutton RA, Deykin D. A chlorpromazine-induced inhibitor of blood coagulation. Am J Hematol. 1977;2(2):183–91.

    Article  PubMed  CAS  Google Scholar 

  40. Zucker S, Zarrabi MH, Romano GS, Miller F. IgM inhibitors of the contact activation phase of coagulation in chlorpromazine-treated patients. Br J Haematol. 1978;40(3):447–57.

    Article  PubMed  CAS  Google Scholar 

  41. Zarrabi MH, Zucker S, Miller F, Derman RM, Romano GS, Hartnett JA, et al. Immunologic and coagulation disorders in chlorpromazine-treated patients. Ann Intern Med. 1979;91(2):194–9.

    PubMed  CAS  Google Scholar 

  42. Canoso RT, Sise HS. Chlorpromazine-induced lupus anticoagulant and associated immunologic abnormalities. Am J Hematol. 1982;13(2):121–9.

    Article  PubMed  CAS  Google Scholar 

  43. Tollefson G, Rodysill K, Cusulos M. A circulating lupus-like coagulation inhibitor induced by chlorpromazine. J Clin Psychopharmacol. 1984;4(1):49–51.

    Article  PubMed  CAS  Google Scholar 

  44. Pavlidakey GP, Hashimoto K, Heller GL, Daneshvar S. Chlorpromazine-induced lupuslike disease. Case report and review of the literature. J Am Acad Dermatol. 1985;13(1):109–15.

    Article  PubMed  CAS  Google Scholar 

  45. Zengotita HE, Holt RJ. Neuroleptic drug-induced coagulopathy: mechanism of reaction and duration of effect. J Clin Psychiatry. 1986;47(1):35–7.

    PubMed  CAS  Google Scholar 

  46. Canoso RT, De Oliveira RM. Chlorpromazine-induced anticardiolipin antibodies and lupus anticoagulant: absence of thrombosis. Am J Hematol. 1988;27:272–5.

    Article  PubMed  CAS  Google Scholar 

  47. Steen VD, Ramsey-Goldman R. Phenothiazine-induced systemic lupus erythematosus with superior vena cava syndrome: case report and review of the literature. Arthritis Rheum. 1988;31(7):923–6.

    Article  PubMed  CAS  Google Scholar 

  48. el-Mallakh RS, Donaldson JO, Kranzler HR, Racy A. Phenothiazine-associated lupus anticoagulant and thrombotic disease. Psychosomatics. 1988;29(1):109–13.

    Article  PubMed  CAS  Google Scholar 

  49. Jude B, Goudemand J, Dolle I, Caron C, Watel A, Tiry C, et al. Lupus anticoagulant: a clinical and laboratory study of 100 cases. Clin Lab Haematol. 1988;10:41–51.

    PubMed  CAS  Google Scholar 

  50. Lillicrap DP, Pinto M, Benford K, Ford PM, Ford S. Heterogeneity of laboratory test results for antiphospholipid antibodies in patients treated with chlorpromazine and other phenothiazines. Am J Clin Pathol. 1990;93:771–5.

    PubMed  CAS  Google Scholar 

  51. Kaslow KA, Rosse RB, Zeller JA, Nagy MS, Deustch SI. Phenothiazine-induced lupus anticoagulant. J Clin Psychiatry. 1992;53(3):103–4.

    PubMed  CAS  Google Scholar 

  52. Morgan M, Chesterman CN, Downs K, Biggs JC. Clinical analysis of 125 patients with the lupus anticoagulant. Aust N Z J Med. 1993;23:151–6.

    Article  PubMed  CAS  Google Scholar 

  53. Gharavi AE, Sammaritano LR, Wen J, Miyawaki N, Morse JH, Zarrabi MH, et al. Characteristics of human immunodeficiency virus and chlorpromazine induced antiphospholipid antibodies: Effect of β2-glycoprotein I on binding to phospholipid. J Rheumatol. 1994;21:94–9.

    PubMed  CAS  Google Scholar 

  54. Tribout B, Gosset O, Fuentes V, Gross S, Fardelonne P, Lernout P, et al. High prevalence of antiphospholipid antibodies without increased risk of thrombosis in psychiatric patients treated chronically with neuroleptic drugs. Nouv Rev Fr Hematol. 1995;37:S79–82.

    Google Scholar 

  55. Matsukawa Y, Satoh M, Itoh T, Nishinarita S, Horie T, Abe K, et al. Plasmapheresis for a schizophrenic patient with drug-induced lupus anti-coagulant. J Int Med Res. 1996;24(1):147–50.

    PubMed  CAS  Google Scholar 

  56. Goldman LS, Hudson JI, Weddington Jr WW. Lupus-like illness associated with chlorpromazine. Am J Psychiatry. 1980;137(12):1613–4.

    PubMed  CAS  Google Scholar 

  57. Dubois EL, Tallman E, Wonka RA. Chlorpromazine-induced systemic lupus erythematosus: case report and review of the literature. JAMA. 1972;221(6):595–6.

    Article  PubMed  CAS  Google Scholar 

  58. Berglund S, Gottfries CG, Gottfries I, Stormby K. Chlorpromazine-induced antinuclear factors. Acta Med Scand. 1970;187(1–2):67–74.

    PubMed  CAS  Google Scholar 

  59. Canoso RT, Romero JA, Yunis EJ. Immunogenetic markers in chlorpromazine-induced tardive dyskinesia. J Neuroimmunol. 1986;12(3):247–52.

    Article  PubMed  CAS  Google Scholar 

  60. Kahn G, Davis BP. In vitro studies on longwave ultraviolet light-dependent reactions of the skin photosensitizer chlorpromazine with nucleic acids, purines and pyrimidines. J Invest Dermatol. 1970;55(1):47–52.

    Article  PubMed  CAS  Google Scholar 

  61. Kanjolia A, Valigorsky JM, Joson-Pasion ML. Clozaril-induced lupus anticoagulant. Am J Hematol. 1997;54(4):345–6.

    Article  PubMed  CAS  Google Scholar 

  62. Alarcon-Segovia D, Fishbein E, Reyes PA, Dies H, Shwadsky S. Antinuclear antibodies in patients on anticonvulsant therapy. Clin Exp Immunol. 1972;12(1):39–47.

    PubMed  CAS  Google Scholar 

  63. Beernink DH, Miller III JJ. Anticonvulsant-induced antinuclear antibodies and lupus-like disease in children. J Pediatr. 1973;82(1):113–7.

    Article  PubMed  CAS  Google Scholar 

  64. Singsen BH, Fishman L, Hanson V. Antinuclear antibodies and lupus-like syndromes in children receiving anticonvulsants. Pediatrics. 1976;57(4):529–34.

    PubMed  CAS  Google Scholar 

  65. Drory VE, Korczyn AD. Hypersensitivity vasculitis and systemic lupus erythematosus induced by anticonvulsants. Clin Neuropharmacol. 1993;16(1):19–29.

    Article  PubMed  CAS  Google Scholar 

  66. Harrison RL, Alperin JB, Kumar D. Concurrent lupus anticoagulants and prothrombin deficiency due to phenytoin use. Arch Pathol Lab Med. 1987;111:719–22.

    PubMed  CAS  Google Scholar 

  67. Becker JC, Winkler B, Klingert S, Brocker EB. Antiphospholipid syndrome associated with immunotherapy for patients with melanoma. Cancer. 1994;73(6):1621–4.

    Article  PubMed  CAS  Google Scholar 

  68. Stricker RB, Barlogie B, Kiprov DD. Acquired factor VIII inhibitor associated with chronic interferon-alpha therapy. J Rheumatol. 1994;21(2):350–2.

    PubMed  CAS  Google Scholar 

  69. Ferraccioli G, Mecchia F, Di PE, Fabris M. Anticardiolipin antibodies in rheumatoid patients treated with etanercept or conventional combination therapy: direct and indirect evidence for a possible association with infections. Ann Rheum Dis. 2002;61(4):358–61.

    Article  PubMed  CAS  Google Scholar 

  70. Ferraro-Peyret C, Coury F, Tebib JG, Bienvenu J, Fabien N. Infliximab therapy in rheumatoid arthritis and ankylosing spondylitis-induced specific antinuclear and antiphospholipid autoantibodies without autoimmune clinical manifestations: a two-year prospective study. Arthritis Res Ther. 2004;6(6):R535–43.

    Article  PubMed  CAS  Google Scholar 

  71. Visvanathan S, Wagner C, Smolen J, St Clair EW, Hegedus R, Baker D, et al. IgG and IgM anticardiolipin antibodies following treatment with infliximab plus methotrexate in patients with early rheumatoid arthritis. Arthritis Rheum. 2006;54(9):2840–4.

    Article  PubMed  CAS  Google Scholar 

  72. Wetter DA, Davis MD. Lupus-like syndrome attributable to anti-tumor necrosis factor alpha therapy in 14 patients during an 8-year period at Mayo Clinic. Mayo Clin Proc. 2009;84(11):979–84.

    Article  PubMed  CAS  Google Scholar 

  73. Makol A, Grover M, Guggenheim C, Hassouna H. Etanercept and venous thromboembolism: a case series. J Med Case Reports. 2010;4:12.

    Article  PubMed  Google Scholar 

  74. Nosbaum A, Goujon C, Fleury B, Guillot I, Nicolas JF, Berard F. Arterial thrombosis with anti-phospholipid antibodies induced by infliximab. Eur J Dermatol. 2007;17(6):546–7.

    PubMed  Google Scholar 

  75. Vereckei E, Krivan G, Reti M, Szodoray P, Poor G, Kiss E. Anti-TNF-alpha-induced anti-phospholipid syndrome manifested as necrotizing vasculitis. Scand J Rheumatol. 2010;39(2):175–7.

    Article  PubMed  Google Scholar 

  76. Ramos-Casals M, Brito-Zeron P, Soto MJ, Cuadrado MJ, Khamashta MA. Autoimmune diseases induced by TNF-targeted therapies. Best Pract Res Clin Rheumatol. 2008;22(5):847–61.

    Article  PubMed  CAS  Google Scholar 

  77. Merkel PA, Lo GH, Holbrook JT, Tibbs AK, Allen NB, Davis Jr JC, et al. Brief communication: high incidence of venous thrombotic events among patients with Wegener granulomatosis: the Wegener’s Clinical Occurrence of Thrombosis (WeCLOT) Study. Ann Intern Med. 2005;142(8):620–6.

    PubMed  Google Scholar 

  78. Sebastian JK, Voetsch B, Stone JH, Romay-Penabad Z, Lo GH, Allen NB, et al. The frequency of anticardiolipin antibodies and genetic mutations associated with hypercoagulability among patients with Wegener’s granulomatosis with and without history of a thrombotic event. J Rheumatol. 2007;34(12):2446–50.

    PubMed  Google Scholar 

  79. Davies R, Galloway JB, Watson KD, Lunt M, Symmons DP, Hyrich KL. Venous thrombotic events are not increased in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis. 2011;70(10):1831–4.

    Article  PubMed  CAS  Google Scholar 

  80. Boxer M, Ellman L, Carvalho A. The lupus anticoagulant. Arthritis Rheum. 1976;19(6):1244–8.

    Article  PubMed  CAS  Google Scholar 

  81. Yokogawa N, Vivino FB. Hydralazine-induced autoimmune disease: comparison to idiopathic lupus and ANCA-positive vasculitis. Mod Rheumatol. 2009;19(3):338–47.

    Article  PubMed  Google Scholar 

  82. Orris DJ, Lewis JH, Spero JA, Hasiba U. Blocking coagulation inhibitors in children taking penicillin. J Pediatr. 1980;97(3):426–9.

    Article  PubMed  CAS  Google Scholar 

  83. Brodeur GM, O’Neill PJ, Willimas JA. Acquired inhibitors of coagulation in nonhemophiliac children. J Pediatr. 1980;96(3 Pt 1):439–41.

    PubMed  CAS  Google Scholar 

  84. Vyse T, So AK. Sulphasalazine induced autoimmune syndrome. Br J Rheumatol. 1992;31(2):115–6.

    Article  PubMed  CAS  Google Scholar 

  85. Alarcon-Segovia D. Drug-induced lupus syndromes. Mayo Clin Proc. 1969;44(9):664–81.

    PubMed  CAS  Google Scholar 

  86. Sheng Y, Kandiah DA, Krilis SA. Anti-b2-glycoprotein I autoantibodies from patients with the “antiphospholipid” syndrome bind to b2-glycoprotein I with low affinity: dimerization of b2-glycoprotein I induces a significant increase in anti-b2-glycoprotein I antibody affinity. J Immunol. 1998;161(4):2038–43.

    PubMed  CAS  Google Scholar 

  87. McNeil HP, Simpson RJ, Chesterman CN, Krilis SA. Anti-phospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: b2-glycoprotein I (apolipoprotein H). Proc Natl Acad Sci USA. 1990;87:4120–4.

    Article  PubMed  CAS  Google Scholar 

  88. Uchman B, Triplett DA. Inhibitor effect of polymyxin B on the X-ase and prothrombinase complex formation. Thromb Haemost. 1989;62:375. Ref Type: Abstract.

    Google Scholar 

  89. Brandt JT, Barna LK, Triplett DA. Laboratory identification of lupus anticoagulants: results of the Second International Workshop for Identification of Lupus Anticoagulants. On behalf of the Subcommittee on Lupus Anticoagulants/Antiphospholipid Antibodies of the ISTH. Thromb Haemost. 1995;74(6):1597–603.

    PubMed  CAS  Google Scholar 

  90. Cajal Y, Ghanta J, Easwaran K, Surolia A, Jain MK. Specificity for the exchange of phospholipids through polymyxin B mediated intermembrane molecular contacts. Biochemistry. 1996;35(18):5684–95.

    Article  PubMed  CAS  Google Scholar 

  91. Packman CH, Leddy JP. Drug-related immune hemolytic anemia. In: Beutler E, Lichtman MA, Coller BS, Kipps TJ, editors. Williams Hematology. New York: McGraw-Hill; 1995. p. 691–7.

    Google Scholar 

  92. Kornberg A, Silber L, Yona R, Kaufman S. Clinical manifestations and laboratory findings in patients with lupus anticoagulants. Eur J Haematol. 1989;42:90–5.

    Article  PubMed  CAS  Google Scholar 

  93. Sanmarco M, Soler C, Christides C, Raoult D, Weiller PJ, Gerolami V, et al. Prevalence and clinical significance of IgG isotype anti-beta-2-glycoprotein I antibodies in antiphospholipid syndrome: a comparative study with anticardiolipin antibodies. J Lab Clin Med. 1997;129(5):499–506.

    Article  PubMed  CAS  Google Scholar 

Download references

Disclosure

No potential conflicts of interest relevant to this article were reported.

Author information

Authors and Affiliations

  1. Quest Diagnostics Nichols Institute, 14225 Newbrook Drive, Chantilly, VA, 20151, USA

    Jeffrey S. Dlott

  2. Thurston Arthritis Research Center and Department of Medicine, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA

    Robert A. S. Roubey

Authors
  1. Jeffrey S. Dlott
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Robert A. S. Roubey
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jeffrey S. Dlott.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Dlott, J.S., Roubey, R.A.S. Drug-Induced Lupus Anticoagulants and Antiphospholipid Antibodies. Curr Rheumatol Rep 14, 71–78 (2012). https://doi.org/10.1007/s11926-011-0227-1

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11926-011-0227-1

Keywords

Search

Navigation